Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-09-07

Nano-X Imaging Ltd.

Nanox develops digital X-ray imaging systems and sells related AI, cloud workflow, teleradiology, and health IT services to healthcare providers.

ai enterprise healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Live-Site Test With Big Equity Torque

This is a distressed medtech workflow story, not just a device story. If installed systems become recurring clinical revenue nodes, the equity can recover sharply; if not, financing pressure will dominate.

Analysis

Thesis

Nanox is a financing-gated option on turning a small base of regulated imaging placements into recurring scan, AI, workflow, and radiology-service revenue; if live-site activations accelerate, the equity can rerate sharply from distress, but the upside depends more on execution and capital discipline than on AI hype alone.

Last Economy Alignment

Moderately positive: Nanox is not a pure software wrapper, so cheaper AI helps its regulated hardware-plus-workflow bundle. But value capture must shift toward managed clinical throughput and trust, because slow activations and OEM bundling can still cap the upside.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

13.9x (from 5 most recent analyses)

Reasoning

The upside is mainly a business-model upgrade, not a shipment tally. If Nanox proves that installed systems become reliable recurring revenue nodes for scans, reports, AI, and workflow support, investors can stop valuing it mainly as a survival case. I still cap the rerating well below premium software names because hardware support, clinical labor, and regulation keep the revenue mix lower quality than elite healthcare software peers.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk story. Nanox first has to preserve liquidity, then convert deployments into active revenue sites, then prove that recurring workflow and services can outrun hardware drag. The company has real regulatory and workflow assets, but financing pressure, slow activation, and OEM bundling risk can break the equity case before the operating model matures.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

A September 4 distribution agreement in New England adds channel reach, but it is still pipeline rather than proof of utilization.
As of September 7, 2026, final Q2 results are still pending for September 9, so near-term price discovery is now centered on runway, burn, and active-site progress.
The September 17 authorized-share vote is now a live financing control point: it improves flexibility if approved, but also highlights that dilution remains central to the story.

Forecast update

End-state value is capped by a more conservative view of revenue quality until live-site utilization, margin mix, and cash-burn improvement are demonstrated.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They control a cleared imaging device plus the software and reading workflow around it, so they can sell a full clinical service instead of just an app. The risk is simple: cash is tight and sites are activating slowly, so bigger imaging vendors could bundle similar tools before Nanox builds real staying power.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$4.33

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research